The Martin's Wellness Commitment We believe in a compassionate approach to health
Overall, the addition of oral semaglutide 7 mg or 14 mg compared favorably to the addition of sitagliptin 100 mg in patients with T2DM inadequately controlled on metformin sulfonylurea background therapy
Patients should continue evidence-based lipid-lowering therapy as recommended by NICE guidelines whilst considering GLP-1 therapy for its licensed indications
Patients with personal MTC history or Multiple Endocrine Neoplasia type 2 (MEN2) syndromewhich includes familial MTCshould not use semaglutide, tirzepatide, or any GLP-1 compound
Researchers Find Small Increased Risk of Sudden Vision Loss Associated With GLP-1 Medications While the risk is low, Rutgers researchers say patients should be aware of this potential association A medication commonly used to treat Type 2 diabetes and obesity was associated with a slight increase in risk for a rare condition involving reduced blood flow to the optic nerve that can cause sudden vision loss, according to Rutgers researchers
Scientists have known for some time that GLP-1 seems to have a secondary function as a satiety signala ping to the brain to stop eating
